Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
Follow-Up Questions
Qui est le CEO de Impact Biomedical Inc ?
Mr. Frank Heuszel est le Chairman of the Board de Impact Biomedical Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action IBO ?
Le prix actuel de IBO est de $0.6633, il a increased de 0.75% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Impact Biomedical Inc ?
Impact Biomedical Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Impact Biomedical Inc ?
La capitalisation boursière actuelle de Impact Biomedical Inc est de $8.0M
